Hepatopulmonary syndromes: Treatment of liver transplantation candidates

Current Opinion in Organ Transplantation

Volumn 7, Issue 2, 2002, Pages 107-113

  O'Callaghan, Dermot ^a   Gaine, Seán P ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALMITRINE DIMESILATE; ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GARLIC EXTRACT; INDOMETACIN; METHYLENE BLUE; N(G) NITROARGININE METHYL ESTER; OCTREOTIDE;

ANESTHESIOLOGICAL TECHNIQUES; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MECHANISM; HEPATOPULMONARY SYNDROME; HUMAN; HUMAN TISSUE; HYPOXIA; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MORTALITY; NONHUMAN; PATIENT SELECTION; PLASMAPHERESIS; PORTAL HYPERTENSION; PROGNOSIS; PULMONARY HYPERTENSION; RAT; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; VASODILATATION;

EID: 0036056945     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075200-200206000-00001     Document Type: Article

References (39)

1. Hepatopulmonary syndrome: Recent literature (1997-1999) and implications for liver transplantation
2. Hepatopulmonary syndrome versus portopulmonary hypertension: Distinctions and dilemmas
3. Structural and pathologic changes in the lung vasculature in chronic liver disease
4. Multiple pulmonary arteriovenous fistulas in juvenile cirrhosis
5. Caveats concerning hepatopulmonary syndrome
6. Pulmonary vascular disorders in portal hypertension
7. The hepatopulmonary syndrome
8. Hepatopulmonary syndrome associated with cardiopulmonary disease
9. Pathophysiology of arterial hypoxemia in advanced liver disease
10. Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics
11. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients
12. Pulmonary hypertension in chronic liver disease
13. Severe pulmonary hypertension in liver transplant candidates
14. Successful liver transplantation in patients with mild to moderate pulmonary hypertension
15. Portopulmonary hypertension and the liver transplant candidate
16. Pulmonary hypertension
17. Distinctive clinical features of portopulmonary hypertension
18. Refractory hypoxemia during liver cirrhosis: Hepatopulmonary syndrome or 'primary' pulmonary hypertension?
19. Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome
20. Severe pulmonary hypertension and amelioration of hepatopulmonary syndrome after liver transplantation
21. Hepatopulmonary syndrome with progressive hypoxaemia as an indication for liver transplantation: Case reports and literature review
22. Long-term outcome of living related liver transplantation for patients with intrapulmonary shunting and strategy for complications
23. Is severe arterial hypoxaemia due to hepatic disease an indication for liver transplantation? a new therapeutic approach
24. Pulmonary hypertension and liver transplantation
25. Association between primary pulmonary hypertension and portal hypertension: Analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations
26. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension
27. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol
28. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates
29. Ancient remedies revisited: Does allium satium (garlic) palliate the hepatopulmonary syndrome?
30. Pulmonary dysfunction in chronic liver disease
31. Methylene blue in the hepatopulmonary syndrome
32. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats
33. High dose calcium channel blocking therapy for primary pulmonary hypertension: Evidence for long term reduction in pulmonary artery pressure and regression of right ventricular hypertrophy
34. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
35. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
36. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension
37. Pulmonary artery hypertension complicating anesthesia for liver transplantation
38. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol